Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Toshimi TakanoNorikazu MasudaMitsuya ItoKenichi InoueYuko TanabeKousuke KawaguchiHiroyuki YasojimaHiroko BandoRikiya NakamuraTakashi YamanakaKazushige IshidaTomoyuki ArugaYasuhiro YanagitaEriko TokunagaKenjiro AogiShinji OhnoHiroi KasaiTatsuki R KataokaSatoshi MoritaMasakazu ToiPublished in: Breast cancer research and treatment (2024)
UMIN-CTR, UMIN000014649, prospectively registered July 25, 2014. Some of the study results were presented as a Mini Oral session at the ESMO Breast Cancer 2023 (Berlin, Germany, 11-13 May 2023).